David A. Siegel Pmv Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Pmv Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 365,400 shares of PMVP stock, worth $591,948. This represents 0.0% of its overall portfolio holdings.
Number of Shares
365,400
Previous 188,600
93.74%
Holding current value
$591,948
Previous $584,000
6.34%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding PMVP
# of Institutions
106Shares Held
45.5MCall Options Held
2KPut Options Held
600-
Orbimed Advisors LLC San Diego, CA6.48MShares$10.5 Million0.25% of portfolio
-
Arrow Mark Colorado Holdings LLC Denver, CO3.2MShares$5.18 Million0.07% of portfolio
-
Black Rock Inc. New York, NY3.11MShares$5.04 Million0.0% of portfolio
-
Euclidean Capital LLC New York, NY2.63MShares$4.26 Million0.57% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.45MShares$3.97 Million0.0% of portfolio
About PMV Pharmaceuticals, Inc.
- Ticker PMVP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,622,600
- Market Cap $73.9M
- Description
- PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also d...